1
|
Azizgolshani H, Coppeta JR, Vedula EM, Marr EE, Cain BP, Luu RJ, Lech MP, Kann SH, Mulhern TJ, Tandon V, Tan K, Haroutunian NJ, Keegan P, Rogers M, Gard AL, Baldwin KB, de Souza JC, Hoefler BC, Bale SS, Kratchman LB, Zorn A, Patterson A, Kim ES, Petrie TA, Wiellette EL, Williams C, Isenberg BC, Charest JL. High-throughput organ-on-chip platform with integrated programmable fluid flow and real-time sensing for complex tissue models in drug development workflows. Lab Chip 2021; 21:1454-1474. [PMID: 33881130 DOI: 10.1039/d1lc00067e] [Citation(s) in RCA: 77] [Impact Index Per Article: 25.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/15/2023]
Abstract
Drug development suffers from a lack of predictive and human-relevant in vitro models. Organ-on-chip (OOC) technology provides advanced culture capabilities to generate physiologically appropriate, human-based tissue in vitro, therefore providing a route to a predictive in vitro model. However, OOC technologies are often created at the expense of throughput, industry-standard form factors, and compatibility with state-of-the-art data collection tools. Here we present an OOC platform with advanced culture capabilities supporting a variety of human tissue models including liver, vascular, gastrointestinal, and kidney. The platform has 96 devices per industry standard plate and compatibility with contemporary high-throughput data collection tools. Specifically, we demonstrate programmable flow control over two physiologically relevant flow regimes: perfusion flow that enhances hepatic tissue function and high-shear stress flow that aligns endothelial monolayers. In addition, we integrate electrical sensors, demonstrating quantification of barrier function of primary gut colon tissue in real-time. We utilize optical access to the tissues to directly quantify renal active transport and oxygen consumption via integrated oxygen sensors. Finally, we leverage the compatibility and throughput of the platform to screen all 96 devices using high content screening (HCS) and evaluate gene expression using RNA sequencing (RNA-seq). By combining these capabilities in one platform, physiologically-relevant tissues can be generated and measured, accelerating optimization of an in vitro model, and ultimately increasing predictive accuracy of in vitro drug screening.
Collapse
Affiliation(s)
- H Azizgolshani
- Draper, 555 Technology Square, Cambridge, MA 02139, USA.
| | - J R Coppeta
- Draper, 555 Technology Square, Cambridge, MA 02139, USA.
| | - E M Vedula
- Draper, 555 Technology Square, Cambridge, MA 02139, USA.
| | - E E Marr
- Draper, 555 Technology Square, Cambridge, MA 02139, USA.
| | - B P Cain
- Draper, 555 Technology Square, Cambridge, MA 02139, USA.
| | - R J Luu
- Draper, 555 Technology Square, Cambridge, MA 02139, USA.
| | - M P Lech
- Pfizer, Inc., 1 Portland Street, Cambridge, MA 02139, USA
| | - S H Kann
- Draper, 555 Technology Square, Cambridge, MA 02139, USA. and Department of Mechanical Engineering, Boston University, 110 Cummington Mall, Boston, MA 02215, USA
| | - T J Mulhern
- Draper, 555 Technology Square, Cambridge, MA 02139, USA.
| | - V Tandon
- Draper, 555 Technology Square, Cambridge, MA 02139, USA.
| | - K Tan
- Draper, 555 Technology Square, Cambridge, MA 02139, USA.
| | | | - P Keegan
- Draper, 555 Technology Square, Cambridge, MA 02139, USA.
| | - M Rogers
- Draper, 555 Technology Square, Cambridge, MA 02139, USA.
| | - A L Gard
- Draper, 555 Technology Square, Cambridge, MA 02139, USA.
| | - K B Baldwin
- Draper, 555 Technology Square, Cambridge, MA 02139, USA.
| | - J C de Souza
- Draper, 555 Technology Square, Cambridge, MA 02139, USA.
| | - B C Hoefler
- Draper, 555 Technology Square, Cambridge, MA 02139, USA.
| | - S S Bale
- Draper, 555 Technology Square, Cambridge, MA 02139, USA.
| | - L B Kratchman
- Draper, 555 Technology Square, Cambridge, MA 02139, USA.
| | - A Zorn
- Draper, 555 Technology Square, Cambridge, MA 02139, USA.
| | - A Patterson
- Draper, 555 Technology Square, Cambridge, MA 02139, USA.
| | - E S Kim
- Draper, 555 Technology Square, Cambridge, MA 02139, USA.
| | - T A Petrie
- Draper, 555 Technology Square, Cambridge, MA 02139, USA.
| | - E L Wiellette
- Draper, 555 Technology Square, Cambridge, MA 02139, USA.
| | - C Williams
- Draper, 555 Technology Square, Cambridge, MA 02139, USA.
| | - B C Isenberg
- Draper, 555 Technology Square, Cambridge, MA 02139, USA.
| | - J L Charest
- Draper, 555 Technology Square, Cambridge, MA 02139, USA.
| |
Collapse
|
3
|
Wright JM, Mattu GS, Perry TL, Gelferc ME, Strange KD, Zorn A, Chen Y. Validation of a new algorithm for the BPM-100 electronic oscillometric office blood pressure monitor. Blood Press Monit 2001; 6:161-5. [PMID: 11518840 DOI: 10.1097/00126097-200106000-00008] [Citation(s) in RCA: 91] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
BACKGROUND To test the accuracy of a new algorithm for the BPM-100, an automated oscillometric blood pressure (BP) monitor, using stored data from an independently conducted validation trial comparing the BPM-100(Beta) with a mercury sphygmomanometer. DESIGN Raw pulse wave and cuff pressure data were stored electronically using embedded software in the BPM-100(Beta), during the validation trial. The 391 sets of measurements were separated objectively into two subsets. A subset of 136 measurements was used to develop a new algorithm to enhance the accuracy of the device when reading higher systolic pressures. The larger subset of 255 measurements (three readings for 85 subjects) was used as test data to validate the accuracy of the new algorithm. METHODS Differences between the new algorithm BPM-100 and the reference (mean of two observers) were determined and expressed as the mean difference +/- SD, plus the percentage of measurements within 5, 10, and 15 mmHg. RESULTS The mean difference between the BPM-100 and reference systolic BP was -0.16 +/- 5.13 mmHg, with 73.7% < or = 5 mmHg, 94.9% < or = 10 mmHg and 98.8% < or = 15 mmHg. The mean difference between the BPM-100 and reference diastolic BP was -1.41 +/- 4.67 mmHg, with 78.4% < or = 5 mmHg, 92.5% < or = 10 mmHg, and 99.2% < or = 15 mmHg. These data improve upon that of the BPM-100(Beta) and pass the AAMI standard, and 'A' grade BHS protocol. CONCLUSION This study illustrates a new method for developing and testing a change in an algorithm for an oscillometric BP monitor utilizing collected and stored electronic data and demonstrates that the new algorithm meets the AAMI standard and BHS protocol.
Collapse
Affiliation(s)
- J M Wright
- Department of Pharmacology & Therapeutics, University of British Columbia, Vancouver, BC, Canada.
| | | | | | | | | | | | | |
Collapse
|
4
|
Gurdon JB, Standley H, Dyson S, Butler K, Langon T, Ryan K, Stennard F, Shimizu K, Zorn A. Single cells can sense their position in a morphogen gradient. Development 1999; 126:5309-17. [PMID: 10556056 DOI: 10.1242/dev.126.23.5309] [Citation(s) in RCA: 52] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Xenopus blastula cells show a morphogen-like response to activin by expressing different genes according to the concentration of activin to which they are exposed. To understand how cells recognize their position in a concentration gradient, it is essential to know whether each cell responds individually to activin concentration. An alternative idea, proposed by previous work, is that cells need to interact with their neighbours to generate a concentration-related response. To distinguish between these ideas, we have cultured blastula cells under conditions which provide different degrees of contact with other cells, allowing nil to maximum communication with their neighbours. The cultures include cells attached to fibronectin and cells resting unattached on an agarose base. The cultures also include cells that have no contact with any cell except their clonal progeny, cells that have lateral contact to neighbouring cells, and cells that are completely enveloped by other cells in a reaggregate. We have used RNase protection and in situ hybridization to assay the expression of the activin-responsive Xenopus genes Xbra, Xgsc, Xeomes, Xapod, Xchordin, Mix1, Xlim1 and Cerberus. We find no difference in gene expression between cells attached to fibronectin and those unattached on agarose. Most importantly, we find that cells respond to activin in a concentration-related way irrespective of their degree of contact with other cells. Therefore interaction among cells is not required for the interpretation of morphogen concentration, at least in the case of the early genes studied here. We conclude that isolated blastula cells can sense and respond individually to activin by expressing genes in a concentration-dependent way.
Collapse
Affiliation(s)
- J B Gurdon
- Wellcome CRC Institute, Tennis Court Road, Cambridge CB2 1QR and Department of Zoology, University of Cambridge, UK.
| | | | | | | | | | | | | | | | | |
Collapse
|